Removing a specific transporter protein from platelet-producing cells stops platelets from becoming overactive when exposed to creatine and reduces the spread of cancer in mice.
See the scientific wording
Knockout of the creatine transporter Slc6a8 specifically in megakaryocytes prevents creatine-supplemented platelet hyperactivity and reduces tumor metastasis in mouse models.
Correlational — new studies may shift this
ObservationalOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Cross-Sectional StudyHuman2026
The study shows that when mice are missing a specific transporter in their platelet-producing cells, creatine supplements no longer make their platelets hyperactive, and cancer spread is reduced.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Creatine, a substance taken as a supplement, enters platelet-producing cells in the bone marrow through a special transporter called Slc6a8. Once inside, creatine boosts the production of an enzyme called creatine kinase B (CKB). This enzyme attaches a phosphate group to a protein called STAT5B, which is not its usual job. The modified STAT5B then turns on genes that make platelets hyperactive. These hyperactive platelets help cancer cells spread to other parts of the body. Knocking out the transporter stops creatine from entering the cells, preventing the whole chain of events and reducing cancer spread.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Removing a specific transporter protein from platelet-producing cells stops platelets from becoming overactive when exposed to creatine and reduces the spread of cancer in mice.
Mechanism
1 studyCreatine enters platelet-producing cells through a specific transporter. Inside, it triggers a chain reaction that makes platelets overly active, helping cancer spread. Removing the transporter stops this process.
Creatine, a substance taken as a supplement, enters platelet-producing cells in the bone marrow through a special transporter called Slc6a8. Once inside, creatine boosts the production of an enzyme called creatine kinase B (CKB). This enzyme attaches a phosphate group to a protein called STAT5B, which is not its usual job. The modified STAT5B then turns on genes that make platelets hyperactive. These hyperactive platelets help cancer cells spread to other parts of the body. Knocking out the transporter stops creatine from entering the cells, preventing the whole chain of events and reducing cancer spread.
Exogenous creatine supplementation increases creatine levels in megakaryocytes via the Slc6a8 transporter.
Elevated creatine upregulates creatine kinase B (CKB) in megakaryocytes.
CKB non-canonically phosphorylates STAT5B.
Phosphorylated STAT5B activates transcription of platelet functional genes.
Expression of these genes leads to hyperactive platelets.
Hyperactive platelets promote tumor metastasis.
Evidence from Studies
Supporting (1)
Community contributions welcome
Exogenous creatine supplementation promotes tumor metastasis via megakaryocyte creatine kinase B-STAT5B signaling.
The study shows that when mice are missing a specific transporter in their platelet-producing cells, creatine supplements no longer make their platelets hyperactive, and cancer spread is reduced.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Slc6a8 Knockout Effects on Platelet Function and Metastasis in Animal Models
Comprehensive search of databases for animal studies comparing Slc6a8 knockout vs wild-type with creatine supplementation, measuring platelet activity and metastasis outcomes. Meta-analysis if possible.
Randomized Controlled Trial of Slc6a8 Knockout vs Wild-Type Mice with Creatine Supplementation for Metastasis
Randomized allocation of mice to knockout or wild-type groups, both receiving creatine supplementation. Primary outcomes: platelet aggregation assay and number of metastatic nodules. Duration: consistent with metastasis model (e.g., 4-6 weeks).
Longitudinal Cohort Study of Slc6a8 Expression Levels and Metastasis Outcomes in Mice
Prospective follow-up of mice with different Slc6a8 genotypes (knockout, heterozygous, wild-type) after tumor cell injection, measuring platele activity and metastasis at multiple timepoints.
In Vitro Platelet Function Assays Comparing Slc6a8 Knockout and Wild-Type Platelets with Creatine
Isolate platelets from knockout and wild-type mice, treat with creatine, measure aggregation, activation markers (e.g., P-selectin), and thrombus formation under flow conditions.
Expert Consensus on the Role of Slc6a8 in Platelet-Mediated Metastasis
Survey or Delphi process involving experts in platelet biology, cancer metastasis, and creatine transport to reach consensus on the mechanism and clinical potential.